Safety, Tolerability and Pharmacokinetic Profile of Levodopa Administered With Continuous Administration of ND0611
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The study hypothesis is that continuous ND0611 increases the bioavailability of levodopa and
therefore the levodopa area-under-the-concentration-curve values, half-life, and trough
concentrations The study will help determining the safety and tolerability of ND0611 and
determine the pharmacokinetic profile of levodopa following multiple oral dosing of
levodopa/carbidopa (LD/CD) and continuous delivery of ND0611